US 7211579

I'll search for authoritative information on this patent number, including any CAFC 2026 docket activity.

Let me run additional targeted searches for any litigation or CAFC activity, and confirm the docket databases.

Let me check for any 2026 appellate activity involving the assignee and confirm the patent's expiration status.

US 7,211,579 B2 — Summary

Bottom line on your request: I found the patent in the USPTO/Google Patents record, but I found no CAFC 2026 docket activity for patent number 7,211,579 in any of my searches. I searched for the patent number against Federal Circuit 2026 docket language and against the current assignee (Helsinn) and found nothing on point. I cannot confirm the absence of a 2026 appeal with high confidence — it may simply not be indexed in the sources I can reach — so treat "no CAFC 2026 docket" as "not found," not as "confirmed none exists."

Bibliographic data (from the authoritative full text)

Conflicts to flag:

• The Google Patents header lists the current assignee as Helsinn Healthcare SA, consistent with the recorded 2014 assignment, but one secondary source (uspto.report) still states the grant is "currently assigned to Hoffmann-La Roche Inc." That appears stale; the assignment record is the better evidence.
• Search snippets returned the status as "Active" in one place, while the full record shows "Expired - Lifetime" with an anticipated expiration of 2026-03-15. Given today's date (April 26, 2026), the term appears to have run. I could not independently verify the post-expiration status in this session.

Abstract

The invention relates to compounds of formula I wherein R is methyl and R¹ is 4-methyl-4-oxy-piperazin-1-yl; or R is CH₂OH and R¹ is 4-methyl-piperazin-1-yl or 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof, for treating NK-1 receptor related diseases (e.g., depression, Parkinson's disease, Alzheimer's disease, anxiety, emesis, and pain).

Claims — plain-language overview

The patent has 5 claims, all independent (claims 3 and 4 name the compounds expressly rather than depending on another claim):

1. Claim 1 — Compound I-1. The single compound 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-4-oxy-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide. Structurally this is the N-oxide form: the piperazine methyl-nitrogen is oxidized to an N-oxide, and the core carries the bis-CF₃-phenyl isobutyramide group and an o-tolyl group on the pyridine. (Context: the corresponding non-oxide piperazine analog is the compound associated with the netupitant lineage via EP 1 035 115 / DE 10008042 — I state that as background inference, not as a claim construction.)

2. Claim 2 — Compound I-3. 2-(3,5-Dimethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(4-methyl-4-oxy-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide. Same pyridine/piperazine-N-oxide scaffold, but the amide aryl is 3,5-dimethyl-phenyl (not bis-CF₃) and the 4-position bears an o-(hydroxymethyl)phenyl group.

3. Claim 3 — Pharmaceutical composition. A therapeutically effective amount of the Claim 1 compound plus a pharmaceutically acceptable carrier.

4. Claim 4 — Pharmaceutical composition. A therapeutically effective amount of the Claim 2 compound plus a pharmaceutically acceptable carrier.

5. Claim 5 — Process. A process for preparing a compound of formula I (R = methyl with R¹ = 4-methyl-4-oxy-piperazin-1-yl; or R = CH₂OH with R¹ = 4-methyl-piperazin-1-yl or 4-methyl-4-oxy-piperazin-1-yl), or a pharmaceutically acceptable acid addition salt, selected from:

   • (a) reacting the piperazine precursor with potassium peroxymonosulfate (2KHSO₅·KHSO₄·K₂SO₄ — OXONE®) to form the N-oxide; and
   • (b) reacting the formyl precursor with NaBH₄ to form the hydroxymethyl compound.

   (The claim as printed closes with the two alternatives and, as rendered, does not include an express "and if desired, converting into a salt" clause; the specification describes salt formation separately.)

Notable substantive points

• Compound I-2 (2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide) is described and made in Example 2 but is not among the individually claimed compounds 1–4; it is covered by the formula-I process claim (branch b).
• The specification asserts comparative advantages over EP 1 035 115: ~8-fold higher solubility for I-2, ~3-fold higher PAMPA permeability, and reduced phospholipidosis potential/metabolic liability for the N-oxide I-1.
• The family includes EP 1863767 B1 and counterparts in ~22 jurisdictions (JP 4768010, KR 100903224, CN 101146775, CA 2602445, AU 2006226665, WO 2006/099968, etc.).
• Cited prior art includes Merck morpholine/tachykinin filings (WO 95/16679, WO 95/18124, WO 95/23798; US 5,972,938), Roche's DE 10008042, EP 1 035 115, EP 1 103 545, and Roche amine-oxide prodrug patents (US 6,593,472 / US 6,747,026).

Uncertainty statement

Everything above the bibliographic table is drawn from the authoritative patent text you supplied. The assignee/status conflicts and the absence of CAFC 2026 docket activity are based on limited searches; I do not have authoritative confirmation of (a) the absence of a 2026 Federal Circuit appeal for 7,211,579, or (b) the exact current legal status as of April 26, 2026. I did not verify the patent number against a live USPTO PatentCenter or PACER/CAFC docket, and I did not auto-correct the identifier — I used "7,211,579" exactly as given.

I'll search for litigation involving US patent 7211579 across litigation databases.

Let me search more specific litigation sources and related parties.

Let me check drug patent litigation databases and the Orange Book listings more specifically.

Summary: No litigation found asserting U.S. Patent No. 7,211,579

Based on targeted searches of litigation-covering sources (Justia dockets, CourtListener/RECAP, Unified Patents portal references, CAFC, and drug-patent litigation trackers such as drugpatentwatch), I found no district-court action, CAFC appeal, ITC investigation, or PTAB post-grant proceeding in which U.S. Patent No. 7,211,579 ("the '579 patent") was itself asserted as a patent-in-suit.

What the searches actually returned

1. No hits on the '579 patent as an asserted patent. Queries for "7,211,579" / "7211579" surfaced:

• The patent's own Google Patents/USPTO record (no litigation tab or "Litigation" family entry for it).
• Unrelated documents where "7211579" is merely an internal docket-entry number (e.g., a Seventh Circuit habeas appeal, Ian Clark v. Mark Sevier, No. 21‑3292, where courtlistener/Judia displays "[7211579]" as an ECF entry ID — not a patent), and a Brazilian state commercial registry filing number. These are false positives and not the patent.

2. The '579 patent appears only as PRIOR ART, not as a cause of action. In Helsinn Healthcare S.A. v. Gland Pharma Ltd., D.N.J. Case No. 2:22‑cv‑04635 (and the corresponding declaratory-judgment/ANDA counterclaim action, D.N.J. No. 2:22‑cv‑04991), Gland's Paragraph IV notice letters and counterclaims attacked the asserted patents covering Akynzeo®. In that context, Gland listed "U.S. Pat. No. 7,211,579 ('Funk')" as prior art in its obviousness contentions against U.S. Pat. No. 8,426,450. This is a citation/defensive use — it does not make the '579 patent a patent-in-suit.

• Reference: Gland's counterclaims/answer, D.N.J. 2:22-cv-04635 (via CourtListener RECAP, doc. 25): https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf

3. Related Helsinn/NK-1 litigation that does NOT involve the '579 patent (listed so you can see the landscape and confirm the distinction):

• Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc. — palonosetron/Aloxi® patents ('724, '725, '424, '219), D.N.J.; Fed. Cir. 2017 (855 F.3d 1356); affirmed by the Supreme Court in Helsinn Healthcare S.A. v. Teva, 586 U.S. ___ (2019) (on-sale bar). The '579 patent was not asserted.
• Helsinn v. Hospira/Worldwide, D.N.J. (Aloxi® ANDA).
• Helsinn v. Gland Pharma ANDA actions (2022) asserting the '450, '586, '357, '772, '907, '073, '911, '721, '297, '698 patents — note: "'721" here is U.S. 10,717,721, a different patent, not 7,211,579.
• PTAB IPRs on other Helsinn patents (e.g., IPR2025‑00945, Azurity v. Helsinn, on U.S. 8,623,826).

Caveats / confidence

• Not high confidence in a definitive "no litigation ever" conclusion. My access was limited to indexed web/aggregator sources and I could not complete a full run through PACER, the Unified Patents litigation caselist, or Darts‑IP. A patent this old (priority 2005; expired per the record) would be an unlikely NPE or branded-pharma assertion target, which is consistent with the null result, but I cannot rule out an old, unindexed suit.
• The '579 patent's ownership history is relevant: originally Hoffmann‑La Roche (assignee), later assigned to Helsinn Healthcare SA (recorded 2014‑09‑25). It is a compound/genus patent tied to the netupitant chemotype but is distinct from the later Helsinn Akynzeo® patents that were litigated.
• I found no PTAB (IPR/PGR) proceeding challenging the '579 patent, and no ITC §337 investigation naming it.

Bottom line: On the evidence retrieved, there is no known litigation (or PTAB/ITC proceeding) specifically involving U.S. Patent No. 7,211,579. Its only documented appearance in litigation is as prior art cited by Gland against a different Helsinn patent. If you need a definitive negative, the next step would be a direct Darts‑IP/Unified Patents caselist and full PACER search, which I was unable to complete within this session.

Would you like me to attempt a narrower follow-up (e.g., a direct Unified Patents litigation-caselist or Darts‑IP lookup) if tool access is restored?

I'll verify the "no proceedings on file" baseline with targeted searches before writing anything.

The Azurity v. Helsinn IPR cluster is the key lead — I need to determine which patent(s) those petitions target.

One more check: whether any IPR was ever filed against the '579 itself (including under the netupitant lineage).

Proceedings overview

AIA trial proceedings on file against US 7,211,579: zero — no Inter Partes Review, no Post-Grant Review, and no Covered Business Method review was ever filed, instituted, or decided against this patent (0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denials). That is both the structured ODP result and the independent search result, so defensive posture is temporal, not PTAB-based: there is no claim-level kill for a defendant to point to, but the patent is recorded "Expired - Lifetime" with an anticipated expiration of 2026-03-15, and today is 2026-09-27 — meaning the claim set appears to have already lapsed, which is a far more complete defense than any FWD could supply.

Important negative-confirmation caveat: I cannot state with high confidence that no petition was ever filed in the patent's 19-year life. What I can state with high confidence from the record is (a) the ODP block reports none, (b) every Helsinn PTAB matter my searches surfaced against the netupitant family targets other patents, and (c) I found no FWD, institution decision, or petition number naming 7,211,579.

Why the "no PTAB activity" result is structurally expected here

Three statutory facts about this patent matter more than any search result:

• PGR was never available. Post-Grant Review applies only to patents with an effective filing date on or after 2013-03-16. The '579 patent was filed 2006-03-15 with EP priority of 2005-03-23 — squarely pre-AIA. No PGR could have been filed, ever, regardless of petitioner interest.
• CBM was never available. The transitional CBM program (2012-09-16 through 2020-09-16) covered only "covered business method" patents in financial services. A pharma compound patent was categorically outside it.
• IPR was the only vehicle — available from 2012-09-16, limited to § 102/§ 103 on patents and printed publications. Any IPR would additionally have been subject to the § 315(b) one-year bar, triggered by service of an infringement complaint.

Adjacent proceedings — NOT against this patent (do not confuse these)

The prior "litigation summary" section correctly noted a Helsinn PTAB cluster on other patents; the full set is now confirmed. A defendant researching "Helsinn PTAB" will land on these, so flagging the distinction explicitly:

• Petitioner / Patent Owner: Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
• Filed: 2025-05-01 (per Docket Alarm docket entries)
• Panel-level activity: Director decision (Coke Morgan Stewart, Acting Under Secretary and Acting Director) denying Helsinn's discretionary-denial requests and referring the petitions to the Board, 2025-09-19; institution granted in at least IPR2025-00948 by decision dated 2025-11-19, with a scheduling order the same day.
• Counsel: Petitioner — Wilson Sonsini (Richard Torczon et al.); Patent Owner — Paul Hastings (Eric Dittmann, Naveen Modi, Isaac Ashkenazi, Chetan Bansal).
• Links: https://www.docketalarm.com/cases/PTAB/IPR2025-00948/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/ ; Director referral decision: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835)/download-documents?artifactId=y6IrpDZshKUiiFxv9niHSqbJgCBiIoOXIntwhciUvoy8nIRpQCyqXDI

None of these challenge 7,211,579, and none generate estoppel as to it. Note also the earlier-litigation observation that in Helsinn v. Gland Pharma (D.N.J. 2:22-cv-04635), the '579 patent appeared only as prior art in Gland's obviousness contentions against US 8,426,450 — a defensive citation, not an assertion: https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf

Strategic summary

Claim status: all five claims UNTESTED and (apparently) all expired. Claims 1–4 (the two specific compounds and their two pharmaceutical compositions) and claim 5 (the OXONE®/NaBH₄ process) were never adjudicated in any AIA trial. There is no FWD cancelling anything, no certificate under § 318(b), and no narrowing amendment. The only claim-differentiating event on this patent's record is the ordinary expiry entry — "Anticipated expiration 2026-03-15" — which, on the Google Patents/USPTO record and given today's date, means the claims have run their 20-year term from the 2006-03-15 filing. I have not independently verified whether any patent term adjustment or terminal disclaimer modified that date, and the record I was given shows no such adjustment.

Estoppel landscape: effectively a blank slate, and that cuts both ways. Because no petitioner ever filed, no one is subject to § 315(e)(2) estoppel as to 7,211,579 — there is no "raised or reasonably could have raised" bar suppressing prior-art grounds. A defendant today could in principle raise any § 102/§ 103 ground from patents and printed publications, plus any § 112 or other invalidity ground in district court. Practically, though, the estoppel question is moot: the patent is expired, so the live defenses are non-infringement (no possibly-infringing acts during the term) and, if damages are sought for past conduct, the invalidity/prosecution-history record. The cited-art corpus is unusually rich for a never-challenged patent — DE 10008042, EP 1 035 115, EP 1 103 545, and Roche's own amine-oxide prodrug patents US 6,593,472 / US 6,747,026 — which the earlier sections noted; note in particular that US 6,593,472 ("NK-1 receptor active amine oxide prodrugs") and US 6,747,026 sit directly on the N-oxide concept that distinguishes claim 1 from the non-oxidized netupitant compound of EP 1 035 115.

Pattern signals. No repeat petitioner, because there was never a first petitioner. No Patent Owner PTAB appeal, because there was never a Board decision to appeal. No defensive aggregator (Unified Patents, RPX, etc.) appears anywhere in the chain for this patent. Helsinn is an aggressive PTAB litigant as a Patent Owner — the 2025 Azurity cluster shows it filing discretionary-denial requests and appointing Paul Hastings to defend the netupitant product patents — but that energy has been directed at the later formulation/combination patents (8,623,826; 9,186,357; 9,943,515; 10,828,297) and their fosnetupitant successors (US 9,403,772; US 8,426,450), not at the '579 compound patent. That asymmetry is the tell: the family's commercial value migrated to the combination and formulation claims, and the '579 N-oxide/compound claims never attracted a challenger.

One further observation a defendant should verify rather than assume: claim 1 (the N-oxide) and claim 2 (the 3,5-dimethyl analog) are not the netupitant molecule itself. Netupitant — 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide — is the non-oxidized piperazine, which is the precursor named in the claim-5 process and is the subject of the earlier EP 1 035 115 / DE 10008042 lineage. If a demand letter invokes 7,211,579 against a netupitant-containing ANDA, the claim-to-product mapping should be tested carefully; I state this as a claim-scope flag for verification, not as a conclusion.

Recommended next steps

• Treat the "no PTAB activity" result as the answer, not as a gap in research — but confirm it directly. The absence here is not the ordinary "the patent got asserted and survived" signal. It is explained by a medical compound patent that expired before reaching the enforcement/vulnerability phase that generates IPRs. Verify the terminal state (expiration date, any PTA, any terminal disclaimer) and the recorded chain — Hoffmann-La Roche Inc. → Helsinn Healthcare SA, reassignment recorded 2014-09-25, effective 2014-09-03 — in USPTO PatentCenter for application 11/376,042: https://patentcenter.uspto.gov/. If real-time confirmation of zero AIA trials is needed, run the patent number through PTAB E2E (https://ptacts.uspto.gov/) rather than relying on web indexes.
• If you are a defendant being asserted against today: lead with the expiry date and the § 318(b)/§ 271 framing, and ask the plaintiff to identify the acts occurring on or before 2026-03-15. There is no FWD to cite and no § 315(e) estoppel to invoke, so your invalidity position is unconstrained by any prior petitioner's choices — but you also have no free-standing "claims 1–5 have been canceled" argument. If the assertion is against a netupitant product, press the claim-charting point above (the claimed compounds are N-oxide / dimethyl analogs, not netupitant as such).
• If you are contemplating a defensive filing: an IPR on an expired patent is legally permissible, and the Board applies the Phillips standard to expired claims — but the § 315(b) one-year clock runs from service of a complaint, and the practical benefit of invalidating already-lapsed claims is close to nil. Spend the budget on the demand-letter response instead.
• Do not cite the Azurity cluster (IPR2025-00945 through -00949) as proceedings "on 7,211,579." They are not. If a vendor, docket alert, or AI summary conflates them with the '579 patent (the "721" / "7,211,579" digit similarity, and the '721 in "US 10,717,721," are the likely sources of confusion), correct the record before relying on it.

I'll research the assignment record details for US 7,211,579, focusing on reel/frame numbers, correspondents of record, and any additional recordings.

I hit the search-step limit before I could pull the correspondent-of-record names from the Assignment Center detail pages. I'll write up what the authoritative record supports and flag precisely what I could not verify. Note that the "Legal Events" table in the supplied Google Patents text is my primary evidence for reel/frame, dates, assignors, and assignees; the correspondent fields were not in that text and I could not retrieve them.

Inventors

Pattern check — no anomaly. All three inventors assigned their rights to F. Hoffmann-La Roche AG by the same instrument (executed 2006-03-07, recorded 2006-06-08, Reel 017760/0519), i.e., a standard employee-assignment-to-corporate-parent. There is no evidence of inventors departing the original assignee within 12 months of filing, no individual/serial-inventor co-ownership, and no post-filing inventor-side re-assignment. The only recurring name is Torsten Hoffmann, who is a repeat Roche NK-1 inventor across the cited family — a normal in-house prolific-inventor pattern, not an NPE tell.

Original assignee

Hoffmann-La Roche Inc. (New Jersey) is the assignee named on the issued patent. It did not receive the rights directly from the inventors: the record shows the standard Roche two-step convention — inventors → F. Hoffmann-La Roche AG (Basel) → Hoffmann-La Roche Inc. (NJ, the U.S. operating/holding entity).

• Primary line of business: F. Hoffmann-La Roche is a large integrated global pharmaceutical and diagnostics company; Hoffmann-La Roche Inc. was its U.S. prescription-pharma operating arm.
• Did it ship a product embodying the claims? No evidence of a Roche-marketed product reading on the claims. The claimed compounds are (i) the N-oxide (I-1, claim 1) and (ii) a 3,5-dimethyl / o-hydroxymethyl analog (I-3, claim 2) of the netupitant chemotype. The commercially marketed product in this lineage — Akynzeo® (netupitant + palonosetron) — contains netupitant, the non-oxidized parent, which is the precursor named in claim 5's process, not a claimed compound. This corroborates the earlier section's flag that '579's claims do not map cleanly onto the marketed molecule.
• Current status: Roche is an operating company (not acquired, dissolved, or in bankruptcy). However, Roche no longer owns this patent — it divested the netupitant compound portfolio to Helsinn in 2014 (see timeline).

Data-quality flag (carry forward): the secondary aggregator uspto.report still lists the grant as "currently assigned to Hoffmann-La Roche Inc." — that is stale. The recorded 2014 assignment to Helsinn Healthcare SA is the better evidence, and the Google Patents "Current Assignee" field agrees.

Assignment timeline

Three substantive assignments are recorded, all in two clusters (2006 and 2014). No security agreements, mergers, changes of name, licenses, releases, or corrections appear.

• 2006-03-07 (executed) / recorded 2006-06-08 — Reel 017760/0519

  • Conveyance: Assignment
  • Assignor: Christoph Funk; Torsten Hoffmann; Andreas Koblet (the three inventors)
  • Assignee: F. Hoffmann-La Roche AG (Grenzacherstrasse, Basel, Switzerland)
  • Correspondent: not determinable from the sources retrieved. (Google Patents "Legal Events" omits the correspondent field, and I could not open the Assignment Center detail page for this reel/frame before the step limit.)
  • Context: inventor-to-employer assignment — the routine first link capturing the inventors' rights in the corporate parent.

• 2006-03-10 (executed) / recorded 2006-06-08 — Reel 017760/0147

  • Conveyance: Assignment
  • Assignor: F. Hoffmann-La Roche AG
  • Assignee: Hoffmann-La Roche Inc. (New Jersey)
  • Correspondent: not determinable (same caveat). Note this record shares the same reel (017760) and the same recording date (2006-06-08) as the prior record, which indicates both were filed together in a single recording submission under one correspondent of record — the practical inference is that the same attorney/firm handled both, but I could not retrieve the name.
  • Context: internal reorg / corporate structuring — the standard Roche parent-to-U.S.-subsidiary step that puts title in the entity named on the patent.

• 2014-09-03 (executed) / recorded 2014-09-25 — Reel 033820/0877

  • Conveyance: Assignment
  • Assignor: Hoffmann-La Roche Inc.
  • Assignee: Helsinn Healthcare SA (Lugano, Switzerland)
  • Correspondent: not determinable from the sources retrieved (detail page not opened). This is a different reel series (033820) from the 2006 filings (017760), indicating a recording roughly eight years later, likely through a different firm/correspondent; unverified.
  • Context: strategic product/portfolio acquisition by an operating company — part of Helsinn's acquisition of the netupitant NK-1 portfolio from Roche (Helsinn had licensed palonosetron from Roche since 1998 and later commercialized the netupitant-palonosetron combination as Akynzeo®). This is the terminal recorded link; no further assignment appears, though Helsinn is the "Current Assignee."

Non-assignment legal events on the same record (for completeness, not ownership changes): 2007-04-11 patent grant; 2010-10-25 4th-year fee (FPAY); 2014-10-23 8th-year fee (FPAY); 2018-10-25 12th-year fee (MAFP). Those fee payments are cosmetic to the ownership chain.

Bottom line for this section: the Assignment Center does have records for this patent (contrary to the "many patents have none" scenario) — exactly three, and the ownership chain is complete and internally consistent. I could not retrieve the correspondent names, which is the one field the task specifically prioritizes; that gap is a verification item, not a finding.

Timeline diagram

timeline
    title Ownership of US 7211579
    2006 : Filed by inventors Funk Hoffmann Koblet
         : Assigned to F Hoffmann-La Roche AG
         : Assigned to Hoffmann-La Roche Inc
    2007 : Patent granted
    2014 : Assigned to Helsinn Healthcare SA
    2026 : Anticipated expiration

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No assignee carries an "IP / Patents / Licensing / Holdings / Ventures" suffix. The terminal assignee, Helsinn Healthcare SA (Reel 033820/0877), is a family-owned operating Swiss pharmaceutical group (founded 1976, Lugano) that develops and commercializes cancer-care drugs (Akynzeo®, Aloxi® lineage) and has GMP manufacturing facilities. That is the opposite of a no-products, registered-agent shell.

2. Known asserter in the chain — not present. Neither Hoffmann-La Roche Inc. nor Helsinn Healthcare SA appears on the public NPE lists referenced (Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Spangenberg entities, etc.). Helsinn does assert patents — Helsinn v. Teva (D.N.J./Fed. Cir. 2017, aff'd 2019) and Helsinn v. Gland Pharma (D.N.J. 2:22-cv-04635/04991) — but as a branded manufacturer suing ANDA filers under Hatch-Waxman, which is operating-company assertion, not NPE activity. No evidence any assignee is a high-frequency plaintiff on a Unified Patents/RPX caselist.

3. Repeat correspondent across the chain — unclear. I retrieved no correspondent names for Reel 017760/0519, 017760/0147, or 033820/0877. One structural inference is available and bears on the signal: the two 2006 records share the same reel (017760) and recording date (2006-06-08), so a single correspondent almost certainly filed both — but because that correspondent is the same firm on both links, it does not carry the NPE "shell LLCs change, the lawyer doesn't" significance. There is also a reel break between 017760 and 033820 (eight years apart), suggesting a different recording agent for the 2014 Helsinn link. Even if a repeat attorney did appear, one recurrence across an intra-corporate step plus a single genuine acquisition is far below the recurrence threshold for a finding. Marked unclear solely because the data were not retrieved, not because anything suspicious was seen.

4. Cascading transfers — not present. Only one post-issuance transfer exists (2014), eight years after the 2006 intra-corporate pair. There is no chain of consecutive assignments through successive LLCs in under 24 months, no shared correspondent address, and no common-principal pattern. The 2014 transfer is a single, terminal hop.

5. Pre-litigation transfer — not present. No infringement suit naming the '579 patent was identified in the prior litigation section, so there is no suit within six months to anchor a "transfer-to-enable-assertion" finding. The 2014 Roche→Helsinn assignment (Reel 033820/0877) precedes the earliest related Helsinn ANDA suits (2022) by roughly eight years — a product-acquisition timeline, not a venue/standing setup.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 by Roche or Hoffmann-La Roche Inc.; no proceeding-sale of the portfolio. Roche is a solvent operating company, and the divestiture was a negotiated portfolio transaction.

7. Privateering — not present / unclear. The shape is a large operating company (Roche) divesting a compound chemotype to a smaller operating company (Helsinn) that then commercializes it. There is no evidence Roche retained a beneficial interest or that Helsinn was asserting on Roche's behalf against Roche's competitors. Helsinn sues ANDA copyists of its own marketed product, which is ordinary Hatch-Waxman conduct. Marked not present on the record available; I did not locate an SEC filing or Patent Progress/EFF piece evidencing an on-behalf-of arrangement. (Helsinn is privately held, so there is no 10-K/8-K paper trail to check in any event.)

8. Defensive aggregator — not present. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. The terminal holder is a manufacturing branded pharma, so the patent has not been neutralized defensively.

Verdict

Operating-company assertion.

Justification: the ownership chain runs from the three Roche inventors through F. Hoffmann-La Roche AG to Hoffmann-La Roche Inc. (Reel 017760/0519 and 017760/0147, both recorded 2006-06-08) and then terminates at Helsinn Healthcare SA (Reel 033820/0877, executed 2014-09-03, recorded 2014-09-25) — a family-owned operating pharmaceutical manufacturer that commercializes the netupitant-palonosetron combination (Akynzeo®) and litigates its Orange Book patents against actual ANDA competitors (Helsinn v. Teva; Helsinn v. Gland Pharma). Zero NPE signals are present; the only "unclear" item (repeat correspondent) is a data-retrieval gap, not an observed pattern. The honest caveat, carried from the earlier sections: the '579 patent itself was never asserted, and the current assignee's marketed molecule (netupitant) is the non-oxidized parent, so the "ships a product embodying the claims" prong is uncertain for this specific patent even though the holder's character is unambiguously operating-company, not NPE.

Verification link (USPTO Assignment Center / Patent Assignment Search): https://assignmentcenter.uspto.gov/ — search by patent number 7211579, or by reel/frame 017760/0519, 017760/0147, and 033820/0877. Mirror index: https://assignment.uspto.gov/patent/index.html.

Confidence and open items.

• High confidence in the three assignment events, their assignors/assignees, execution dates, recording dates, and reel/frame numbers — these come from the patent's own Legal Events record, which the earlier sections also treated as authoritative.
• Not verified (task-critical gap): the correspondent of record for each reel/frame. I could not open the Assignment Center detail pages before hitting the search-step limit, so I have not named any attorney or firm and have not evaluated signal #3 against actual correspondent data.
• I did not independently confirm there are no further assignments recorded after 2014 (e.g., an unindexed later transfer); the Google Patents record shows none, and the "Current Assignee = Helsinn Healthcare SA" field is consistent with that, but a direct Assignment Center query is the controlling check.
• No identifier was auto-corrected; "7211579" / "7,211,579" / "11/376,042" and all reel/frame values are reproduced exactly as recorded.

I'll research the cited prior-art references for US 7,211,579, focusing on which ones are most relevant to the claims.

Let me get more detail on the two references that appear most structurally on-point for the claimed N-oxide and hydroxymethyl compounds.

Prior-Art Analysis — US 7,211,579 B2 ("NK-1 receptor antagonists")

Building on the bibliographic/claims work already generated: this is a pre-AIA patent (US filing 2006-03-15; effective filing/priority 2005-03-23), so the operative gates are pre-AIA § 102(a), (b), and (e) and § 103(a). The five claims for reference (from the earlier section):

Critical date: any reference published, or US application filed, before 2005-03-23 is prior art. Note one citation (US 2005/0090533) publishes after that date and is only § 102(e) art at best.

A. The 12 cited patent references (from the "Patent Citations" list)

Dates are the publication date and, in parentheses, the cited priority/filing date. "Examiner" flags = the asterisk convention in the record ('*' = cited by examiner); the un-starred entries read as applicant/background citations.

1. WO 95/16679 A1 — Morpholine and thiomorpholine tachykinin receptor antagonists

• Assignee: Merck & Co., Inc.; published 1995-06-22 (priority 1993-12-17).
• Description: Broad genus of morpholine/thiomorpholine NK-1 (substance P) antagonists. Cited in the '579 background for the proposition that substance P is implicated in CNS disorders.
• § 102 impact: Different chemotype (morpholine/thiomorpholine core, not the 4-aryl-pyridine bis-CF₃ isobutyramide scaffold). Does not anticipate any of claims 1–5. Background/§ 103 context only.

2. WO 95/18124 A1 — Substituted morpholine derivatives and their use as therapeutic agents

• Assignee: Merck Sharp & Dohme Ltd.; published 1995-07-06 (priority 1993-12-29).
• Description: Morpholine-based tachykinin antagonists.
• § 102 impact: Same reasoning as #1 — no anticipation of any claim; structurally remote.

3. WO 95/23798 A1 — Prodrugs of morpholine tachykinin receptor antagonists

• Assignee: Merck & Co., Inc.; published 1995-09-08 (priority 1994-03-04).
• Description: Prodrug forms of morpholine NK-1 antagonists. Conceptually relevant because it teaches the prodrug/N-oxide design concept, but on a morpholine chemotype.
• § 102 impact: Does not anticipate claims 1–5 (no 4-aryl-pyridine piperazine substrate; no OXONE/NaBH₄ process on the claimed intermediates). It is, however, § 103 context for the "make a prodrug of a basic-amine NK-1 antagonist" motivation.

4. US 5,972,938 A — Method for treating or preventing psychoimmunological disorders

• Assignee: Merck & Co., Inc.; filed 1997-12-01, granted 1999-10-26.
• Description: Method-of-treatment claim (administration of a tachykinin/NK-1 antagonist for psychoimmunologic/psychosomatic disorders). Cited in the '579 background.
• § 102 impact: Method claims cannot anticipate the compound (1–2), composition (3–4), or process (5) claims of '579. No anticipation; background art only.

5. DE 10008042 A1 — Neurokinin-1 receptor antagonist ⭐ key

• Assignee: Hoffmann-La Roche; priority 1999-02-24, published 2000-08-31.
• Description: The Rosetta-stone reference for this family. The '579 specification expressly states that its starting materials/intermediates are "synthesis described in DE10008042" — including 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide (the non-oxide parent of claim 1's I-1) and N-[4-iodo-6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-2,2-dimethyl-propionamide.
• § 102 impact:
  • Claim 1 — no anticipation: DE 10008042 discloses the piperazine compound but not the N-oxide (the 4-oxy oxygen is a missing element).
  • Claim 2 — no anticipation: it does not disclose the 3,5-dimethyl-phenyl / 2-hydroxymethyl-phenyl / N-oxide combination.
  • Claim 5 — no anticipation: it does not disclose the OXONE® oxidation or the NaBH₄ reduction step to the claimed products.
  • But it is the single most probative § 103 reference: it supplies the entire claimed skeleton except the N-oxide oxygen and the 3,5-dimethyl/hydroxymethyl variations.

6. EP 1 035 115 A1 — 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists ⭐ key

• Assignee: F. Hoffmann-La Roche AG; priority 1999-02-24 (and 1999-11-29), published 2000-09-13.
• Description: Broad 4-phenylpyridine NK-1 antagonist genus (R/R¹ up to a 4-substituted phenyl; R⁴ can be a cyclic tertiary amine such as piperazin-1-yl/morpholin-4-yl; R⁵ can be hydroxyl-lower alkyl, —CHO, etc.). This is the reference the '579 specification itself names as the "structurally-related" comparison compound for solubility/permeability, and the Roche derivative document (DE 60123661 T2) identifies, as compounds whose synthesis is "in EP-A-1035115," both the morpholine and the 4-methyl-piperazin-1-yl 4-o-tolyl isobutyramide compounds.
• § 102 impact:
  • Claim 1 — no anticipation: EP 1 035 115 discloses the non-oxidized piperazine compound; it does not disclose the N-oxide.
  • Claim 2 — no clear anticipation: its generic formula reaches hydroxymethyl/CHO-bearing phenyl groups, but I found no disclosure of the specific 3,5-dimethyl-phenyl + N-oxide-piperazine species of I-3. Genus disclosure of a substituent class does not normally anticipate a specific species unless the species is "described."
  • Claim 5 — no anticipation.
  • Primary § 103 reference (expressly conceded as the closest art in the specification).

7. EP 1 103 545 A1 — 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide

• Assignee: F. Hoffmann-La Roche AG; priority 1999-11-29, published 2001-05-30.
• Description: A specific-compound patent directed to the morpholine analog (R⁴ = morpholin-4-yl). The '579 specification names EP 1 103 545 A1 alongside EP 1 035 115 as the "similar compounds" prior art.
• § 102 impact: The morpholine ring is a different heterocycle from the 4-methyl-4-oxy-piperazin-1-yl required by claim 1. No anticipation of claims 1–4 (missing piperazine/N-oxide element); § 103 art.

8. US 6,479,482 B2 — Alkylamine derivatives of dihydropyridine NPY antagonists (examiner-cited)

• Assignee: Bristol-Myers Squibb; priority 2000-05-10, granted 2002-11-12.
• Description: Dihydropyridine alkylamines as NPY (not NK-1) antagonists.
• § 102 impact: Different receptor target and different chemotype. No anticipation of any claim; the citation appears to be general "amides/alkylamines in the art" art.

9. US 6,593,472 B2 — NK-1 receptor active amine oxide prodrugs (examiner-cited) ⭐⭐ most material for claim 1

• Assignee: Hoffmann-La Roche Inc. (Hoffmann, Poli, Schnider, Sleight); priority/filed 2000-07-14, granted 2003-07-15.
• Description: Claims N-oxides of 4-phenylpyridine NK-1 antagonists as prodrugs. The genus explicitly embraces a 5- or 6-membered N-heterocycle formed by R⁴/R⁴′ (optionally with one additional N/O/S heteroatom) — i.e., piperazine rings — with the ring nitrogen oxidized to the N-oxide. Preferred-compound lists include piperazine-N-oxide nicotinamides (e.g., an "1-oxy-piperazin-1-yl"-bearing compound) and 4-oxy-morpholine analogs; sibling members of the same family include US 6,747,026 B2, US 2003/0149039 A1 and US 2004/0048901 A1.
• § 102 impact:
  • Claim 1 — closest § 102 candidate. It discloses the same core (bis-CF₃-phenyl isobutyramide on a 4-o-tolyl-pyridine) with a piperazine-N-oxide at the 6-position — the very feature that distinguishes claim 1 from DE 10008042/EP 1 035 115. If the specification's species list expressly names the 4-methyl-4-oxy-piperazin-1-yl compound (as distinguished from its 4-formyl-piperazine N-oxide analogs), claim 1 is potentially anticipated. I could not confirm the exact I-1 species is named, so treat this as "potentially anticipating if a species disclosure exists" and, at minimum, a highly material § 103 reference (it supplies the N-oxide element as a known, Roche-owned modification of exactly this scaffold).
  • Claims 2–4 — no anticipation, but § 103-relevant (it teaches that oxidizing the basic piperazine nitrogen of this scaffold is an established, analogous modification).

10. US 2003/0083345 A1 — Method of treatment and/or prevention of brain, spinal or nerve injury (examiner-cited)

• Inventor/Assignee: Torsten Hoffmann (Roche); priority 2001-07-10, published 2003-05-01.
• Description: Method claims administering NK-1 antagonists (including 4-phenylpyridine compounds such as the 6-morpholin-4-yl-4-o-tolyl and 6-(4-oxy-morpholin-4-yl)-4-o-tolyl isobutyramides) for nerve injury.
• § 102 impact: Method-of-use disclosure; no anticipation of the compound/composition/process claims 1–5. It does corroborate that N-oxide ("4-oxy-morpholine") variants of this scaffold were known before the critical date (§ 103 context).

11. WO 2005/002577 A1 — Dual NK1/NK3 antagonists for treating schizophrenia (examiner-cited)

• Assignee: F. Hoffmann-La Roche AG; priority 2003-07-03, published 2005-01-13.
• Description: Dual NK1/NK3 antagonists (different scaffold).
• § 102 impact: Published before the critical date (so § 102(b) art), but structurally remote from the claimed single-target compounds. No anticipation of any claim.

12. US 2005/0090533 A1 — Dual NK1/NK3 receptor antagonists (examiner-cited)

• Inventor: Torsten Hoffmann; priority 2003-07-03, published 2005-04-28.
• Description: Dual NK1/NK3 antagonists (the US counterpart of WO 2005/002577).
• § 102 impact: Published after the 2005-03-23 critical date, so it is not § 102(a)/(b) art; at most § 102(e) art if its US filing predates the '579 priority. Structurally remote. No anticipation of any claim.

B. Claim-by-claim anticipation map (single-reference § 102)

Net: on the citations of record, the strongest single-reference § 102 exposure is claim 1 vs. US 6,593,472 (unconfirmed), and the strongest overall § 103 exposure is claims 1–4 over DE 10008042 or EP 1 035 115 in view of US 6,593,472.

C. Most relevant prior art (ranked)

1. US 6,593,472 B2 (+ siblings US 6,747,026 B2, US 2003/0149039, US 2004/0048901) — NK-1 receptor active amine oxide prodrugs: supplies the N-oxide-of-a-piperazine element that separates claim 1 from the Roche base compounds. Most material reference.
2. DE 10008042 A1 — discloses the exact non-oxidized parent and the intermediates the '579 patent uses (expressly cited as its synthesis source).
3. EP 1 035 115 A1 — the 4-phenylpyridine genus the specification itself concedes as the "structurally-related" art.
4. EP 1 103 545 A1 — the morpholine analog (specific-compound patent).
5. WO 95/23798 A1 — prodrug concept on a morpholine chemotype (§ 103 motivation).
6. Everything else (Merck morpholine filings, US 5,972,938, US 6,479,482, WO 2005/002577, US 2005/0090533, US 2003/0083345) — background/remote; no anticipation.

The seven non-patent citations (Barker 1996; Halliwell 1997; Kramer 1998; Longmore 1997; Lüllmann 1978; Maggi 1993; Navari 1999) are utility/mechanism and phospholipidosis references — they support enablement/utility and the N-oxide safety argument but anticipate no claim.

D. Caveats and confidence

• Confirmed from the authoritative text: the 12-item citation list, all publication/priority dates, the specification's express reliance on DE 10008042 for intermediates, and its express comparison to EP 1 035 115 / EP 1 103 545.
• Not fully verified in this session (search step limit reached): the complete claim sets/species lists of US 6,593,472, DE 10008042, WO 95/16679/18124/23798, and US 5,972,938. My descriptions of items 1–4 are based on their titles, assignees and standard-of-the-art knowledge of the Merck morpholine series, plus partial snippets — treat items 1–4 and 8 as provisional.
• The one place a § 102 conclusion could flip: whether US 6,593,472 (or US 6,747,026) names the specific N-methyl-4-oxy-piperazin-1-yl species of claim 1. If it does, claim 1 is arguably anticipated; if it only discloses the genus (piperazine N-oxides generally) or a 4-formyl-piperazine N-oxide, anticipation fails and the reference is § 103 art. Recommend a direct full-text/claim check of US 6,593,472 and US 6,747,026 before relying on either conclusion.
• I did not auto-correct any identifier; the references are reported exactly as listed.
• Anticipation vs. obviousness is a legal conclusion; the above is a technical mapping of disclosures to claim elements, not a legal opinion.

I'll ground the key prior-art references before building the §103 analysis.

Strong grounding so far. Let me pin down two things: (a) whether the Roche amine-oxide patents expressly disclose a piperazine N-oxide on this scaffold, and (b) any prior art with a 3,5-dimethylphenyl amide (relevant to claim 2).

Obviousness Analysis — U.S. Patent No. 7,211,579 under 35 U.S.C. § 103

Note on inputs. This analysis uses the prior-art section of the US 7,211,579 page you supplied (the 12 "Patent Citations," the 7 "Non-Patent Citations," and the "Similar Documents" list), plus targeted retrieval of the underlying references. References I pulled that are not on the '579 face are labeled as such. I did not re-verify anything against PACER/USPTO PatentCenter. I also flag one date inconsistency: the session header says 2026-09-27 while the task states April 26, 2026; I rely only on the patent's own recorded expiration (2026-03-15, "Expired - Lifetime"), which is in the past under either date — so a §103 challenge now matters for past-damages validity, not for prospective infringement.

1. The claims to be tested

POSITA. A medicinal/organic chemist with a Ph.D. (or M.S. + several years) in CNS/neuropeptide drug discovery, familiar with (i) the 4-phenylpyridine NK-1 antagonist SAR then in the literature (Maggi 1993; Kramer 1998; Navari 1999 — all of record), (ii) standard functional-group transformations (tertiary-amine N-oxidation; NaBH₄ reduction; Pd-catalysed Suzuki coupling; amide coupling with KHMDS/MeI alkylation — the exact sequence in the '579 Example 2), and (iii) prodrug/metabolite-stability design.

2. The operative prior art

Corroboration that the N-oxide family was aimed at exactly this problem: Helsinn's own later patent US 9,908,907 B2 states in its background that "Mono-N-oxide derivatives of 4-phenyl-pyridine compounds are described in U.S. Pat. No. 6,747,026 to Hoffmann-La Roche. These N-oxide derivatives are reportedly intended to overcome limitations on the parent compounds that would otherwise limit their clinical usefulness, such as solubility or pharmacokinetic limitations."

3. Claim-by-claim

Claim 1 — strong §103 case

Combination A: EP 1 035 115 (or DE 100 080 42) + US 6,593,472 / US 6,747,026 (+ US 2004/0048901), optionally + Halliwell/Lullmann.

The only structural difference between Claim 1 and the prior art is the N→O bond. Every other atom, ring, and substituent is disclosed.

Motivation to combine (KSR factors; no hindsight needed):

1. Same field, same inventors, same chemotype, same utility. Not a cross-discipline leap — the primary and secondary references are Roche filings on the same 4-phenylpyridine nicotinamide/isobutyramide class, with overlapping inventorship (Torsten Hoffmann appears on both sides). MPEP §2144.04 example (i)/(iii) applies directly: an express teaching in one of the references that the improvement is desirable.
2. The secondary reference is the improvement. US 6,593,472 / 6,747,026 claim N-oxides of this exact scaffold (claim 5 of the '472 is the o-tolyl/bis-CF₃ isobutyramide with a 4-oxy-morpholin-4-yl; claims 16–17 cover N-oxides of acyclic amino variants on the same core). Fetching the genus to the piperazine case is a 1-position change — the '472 genus already recites a 5-/6-membered N-heterocycle N-oxide containing "0 or 1 additional hetero atoms … nitrogen," which reads on piperazine-N-oxide, and US 2004/0048901 goes further and names a 1-oxy-piperazin-1-yl species on the same 4-o-tolyl core.
3. Design incentive is documented, not inferred. The N-oxide is disclosed as a prodrug/solubility-and-PK solution in the '026/'472 family (per the Helsinn background quote above), and the record on the '579 face itself supplies the toxicity rationale — Halliwell 1997 and Lullmann 1978 on cationic amphiphilic drug-induced phospholipidosis. The '579 specification concedes the parent "has the potential to produce phospholipidoses … due to the fact that it contains a basic nitrogen atom, which may protonate under physiological conditions," and that the N-oxide's stated advantage is simply that "the N-oxide is neutral." A POSITA with a basic tertiary amine and a known phospholipidosis concern would neutralize it — N-oxidation is the textbook maneuver.
4. Reasonable expectation of success. N-oxidation of a tertiary aliphatic amine is routine and high-yielding; the '472/'026 family runs it on this scaffold in ~15–85% yield ("potassium peroxymonosulfate in water" among the recited reagents). No unpredictable property is at issue.
5. No teaching away. The only potential "away" signal — that N-oxides reduce back to the parent in vivo — is expressly characterised in the '026 family as the desired prodrug mechanism.

Regiochemistry nuance (the patentee's best structural argument, but weak). In Claim 1 the N-oxide sits on the distal (N-methyl) nitrogen; the '226/'026 species I identified oxidizes the ring-attached nitrogen of a related piperazine. A POSITA would nonetheless predict the claimed regioisomer: on a piperazine attached to an electron-poor pyridine, the distal N-methyl nitrogen is the more basic, more nucleophilic site, and is therefore the preferentially oxidized one. Example 1 of the '579 patent (80% yield, single product) is consistent with the expected outcome — predictable regioselectivity does not create patentability.

Bottom line: Claim 1 would more likely than not be held obvious (or, at minimum, squarely "obvious to try with a reasonable expectation of success," KSR).

Claim 2 — weaker §103 case; the weak link is 3,5-dimethyl

Combination B: EP 1 035 115/DE 100 080 42 + US 6,593,472/6,747,026 + WO 2005/014549 (EP 1 656 351).

• 6-(4-methyl-4-oxy-piperazin-1-yl): obvious on the Combination A reasoning.
• 4-(2-hydroxymethyl-phenyl): WO 2005/014549/EP 1 656 351 discloses R4 = "-CHO or hydroxyl-lower alkyl" (formyl/hydroxymethyl) on the 4-aryl of 4-aryl-nicotinamides whose 6-position is a cyclic tertiary amine including piperazin-1-yl. So 2-(hydroxymethyl)phenyl on this scaffold is disclosed, not merely suggested.
• 3,5-dimethyl-phenyl amide aryl: this is where I cannot complete the case. The Roche genus definitions of record (EP 1 035 115; EP 1 656 351) enumerate the 3,5-amide-aryl substituents as hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano — methyl is not among them. I could not locate a reference that expressly discloses or suggests 3,5-dimethyl in that position, and I was cut off before running a dedicated search for it.

So Claim 2 would have to rest on a "predictable variation / homologation" argument — that PR₂/PR₂′ in this SAR is a generic hydrophobic 3,5-disubstituted aryl pocket tolerant of dimethyl ⇄ bis-CF₃ interchange — supported by the fact that the reference genera explicitly contemplate multiple lipophilic 3,5-substituents (CF₃, halogen, alkoxy). That is a real but contestable argument. Rank: Claim 1 >> Claim 5 > Claim 2 ≈ Claim 4.

⚠️ Flag — internal inconsistency in Claim 2. As granted, Claim 2 recites 2-(3,5-dimethyl-phenyl). But formula I as disclosed (and replicated in Claim 5) fixes the amide aryl as 3,5-bis(trifluoromethyl)phenyl. Compound I-3 as claimed therefore sits outside the disclosed compound set. The sibling PCT/AU disclosure (WO 2006/09968 / AU 2006226665, per the "Object of the present invention" listing retrieved) names I-3 as the 3,5-bis-CF₃ hydroxymethyl N-oxide — i.e., consistent with formula I, inconsistent with the U.S. grant. The description of the '579 page also carries SMILES strings for what appear to be 3-methyl-5-CF₃ variants (e.g. SWBNHEPTGDPBDJ, OYGYSFWWHCNEKQ) alongside the 3,5-dimethyl species (GJQSRQQILUQBGR). Treat these as a claim-support / written-description problem (§112(a)) that a challenger would plead together with the §103 ground for Claim 2, and as a possible certificate-of-correction issue — not as §103 evidence.

Claims 3 and 4 — obvious derivatively

Once the compounds are obvious, a "composition comprising a therapeutically effective amount of [that compound] and a pharmaceutically acceptable carrier" adds nothing inventive: the carrier elements are conventional (lactose, corn starch, talc, stearic acid, water/polyols, suppository bases — the '579 specification's own Examples A–C use exactly these, and the amine-oxide references also disclose pharmaceutical compositions of their N-oxides). Under KSR, the composition is the predictable, market-driven packaging of the compound. Claim 3 is therefore obvious with Claim 1; Claim 4 is only as strong as Claim 2.

Claim 5 — strong §103 case; near-anticipatory for branch (a)

Combination C: EP 1 035 115/DE 100 080 42 (substrates) + US 3/0149039 (═ US 6,593,472/6,747,026 family), ¶[0096]–[0099].

• Branch (a), OXONE® N-oxidation: the secondary reference states, in the same breath as its own formula-I-to-formula-II oxidation, that "other oxidizing reagents may be used instead of 3-chloroperbenzoic acid … such as dimethyldioxirane in acetone, hydrogenperoxide in acetic acid or potassium peroxymonosulfate in a suitable solvent such as water." That is a per se disclosure of the claimed reagent for the claimed transformation on the claimed substrate class — i.e., the reagent and the step are handed to the POSITA. Motivation: routine selection of a known oxidant on a disclosed substrate; the claimed 80% yield is consistent with the reference's own reported range.
• Branch (b), NaBH₄ reduction: sodium borohydride reduction of an aryl aldehyde to a primary benzylic alcohol is a textbook transformation. The substrate (the 2-formyl-phenyl compound) is disclosed/suggested by WO 2005/014549 ("-CHO" alkyl-linked aryl), and the '579 Example 2 itself makes the aldehyde by standard Suzuki coupling with 2-formylphenylboronic acid before reducing it. "Obvious to try" collapses to near-zero here.
• Claim structure note: the two branches are alternatives ("selected from the group consisting of"). Each is independently obvious, so the claim fails on either alternative (single-species logic of In re Meyer applies mutatis mutandis to obviousness).

4. Aggregate mapping

Key structural point about the prior art web: the secondary reference in Combination A/C is not merely analogous art — its own specification says its starting materials "may be prepared in accordance with methods, described in EP 1035115." That express linkage is the single strongest anti-obviousness-defence fact, because it eliminates any argument that a POSITA would not have consulted the two together.

5. Anticipated rebuttals and secondary considerations

6. Contradictions / things to flag

1. Claim 2 vs. formula I — the granted Claim 2 compound (3,5-dimethyl amide aryl) falls outside the disclosed formula I, which hard-codes 3,5-bis(trifluoromethyl)phenyl; the PCT/AU sibling lists I-3 as the bis-CF₃ N-oxide. This is a §112(a) support defect and a potential correction issue, and it is a genuine cross-reference conflict with the earlier sections of this file (which treated I-3 as a formula-I compound).
2. Regiochemistry of the N-oxide — Claim 1's N-oxide is on the distal N-methyl nitrogen; the closest species-level piperazine N-oxide I located (US 2004/0048901 / US 6,897,226) is on the ring-attached nitrogen. Predictable, but a distinction the patentee can (weakly) press.
3. Date conflict — session header 2026-09-27 vs. task date April 26, 2026. Immaterial to the §103 analysis, but noted because both post-date the recorded 2026-03-15 expiration.
4. Prior-art reference that is not of record — WO 2005/014549 / EP 1 656 351 B1 (pub. 2005-02-17) is materially relevant to Claim 2 (hydroxymethyl/formyl 4-aryl) but does not appear on the '579 face. Any challenge would need it added.
5. Pre-AIA §103(c) caveat. This is a 2006-filed, pre-AIA case. Several candidate secondary references are Roche-owned (as was the '579 application). §103(c) disqualifies only art that qualifies "solely" under §102(e)/(f)/(g). The references carrying the most weight are safe: EP 1 035 115 (2000), DE 100 080 42 (2000), US 6,593,472 (2003-07-15), US 6,747,026 (2004-06-08), US 2004/0048901 (2004-03-11) are all printed publications/patents more than one year before the 2005-03-15 §102(b) critical date, hence §102(a)/(b) art not reached by §103(c). WO 2005/014549 (pub. 2005-02-17) is the one that could be argued as §102(e)-only art (as to any U.S. national-phase counterpart) and therefore potentially disqualified by common ownership; as a printed publication under §102(a) it stands.

7. Bottom line

• Claim 1 and Claim 5 are, in my assessment, clearly vulnerable to §103 over EP 1 035 115 / DE 100 080 42 + the Roche amine-oxide family (US 6,593,472 / US 6,747,026 / US 2004/0048901 / US 2003/0149039), with the phospholipidosis literature (Halliwell 1997; Lullmann 1978) supplying the articulated problem. The secondary reference's express cross-reference to EP 1035115 defeats any "not combinable" or "different field" defence, and the reference expressly recites the very oxidant (potassium peroxymonosulfate) claimed in Claim 5(a).
• Claim 3 falls with Claim 1.
• Claim 2 (and therefore Claim 4) is the resistant claim, not because of any unexpected property but because I could not locate art disclosing/suggesting the 3,5-dimethyl amide aryl; the challenge there would need a generic 3,5-aryl-pocket/"predictable variation" argument plus the §112(a) support defect arising from the formula-I misalignment.
• Confidence: high on the reference contents and the combination logic for Claims 1/3/5; low-to-moderate on Claim 2, because (a) the 3,5-dimethyl limitation is unmatched in the art I could reach, and (b) my searches were terminated before I could run a dedicated 3,5-dimethylphenyl/NK-1 query. I have not verified any of this against a live USPTO/PTAB record, and I did not auto-correct any identifier — "7211579," "7,211,579," "EP 1 035 115," "DE 10008042," "US 6,593,472," and "US 6,747,026" are reproduced exactly as they appear in the sources.